Company Research

Leidos Holdings, Inc. (LDOS)

Scanner score: 48.00Price: $128.25ROE: 28.27%Margin of safety: 55.79%

First analyzed: 2026-09-28

Part 1

Company Overview

Leidos is a large, government-focused technology and mission-services contractor whose durable advantages are customer trust, contract vehicles, security clearances, domain expertise, and scale, but whose long-term economics remain exposed to federal budgets, recompetes, contract execution, and acquisition integration.

Business Model

Overview

  • Leidos provides technology, engineering, systems integration, health services, security products, and mission-support services to government and commercial customers.
  • The company earns revenue primarily through negotiated contracts as a prime contractor or subcontractor. Its offerings include software and digital services, cyber and intelligence support, defense systems, managed health services, transportation and security systems, engineering, and critical-infrastructure services.
  • Beginning in fiscal 2026, Leidos realigned its reporting structure into four segments: Intelligence & Digital, Health, Homeland, and Defense. Prior-year results were recast for comparison.

Segments

  • Segment

    Intelligence & Digital

    Description

    Supports intelligence, defense, cyber, digital modernization, mission software, analytics, and related technology programs.

    Fiscal 2025 Revenue

    $7.365 billion under the prior reporting structure, equal to approximately 44.2% of company revenue.

    Current 2026 Indicator

    Revenue was $3.012 billion in the first six months of fiscal 2026, or approximately 33.6% of company revenue for that period.

  • Segment

    Health

    Description

    Provides health-services administration, military and veteran health support, medical evaluations, clinical services, and related technology.

    Fiscal 2025 Revenue

    $5.015 billion under the prior reporting structure, equal to approximately 30.1% of company revenue.

    Current 2026 Indicator

    Revenue was $2.274 billion in the first six months of fiscal 2026, or approximately 25.4% of company revenue for that period.

  • Segment

    Homeland

    Description

    Provides transportation security, border and immigration systems, aviation and airport technology, screening systems, infrastructure engineering, and related homeland-security services. The 2026 segment includes the acquired Entrust power and utilities engineering business.

    Fiscal 2025 Revenue

    The comparable prior structure reported $2.252 billion for Commercial & International, equal to approximately 13.5% of fiscal 2025 company revenue. This is not directly comparable with the current Homeland segment because the reporting composition changed.

    Current 2026 Indicator

    Revenue was $1.834 billion in the first six months of fiscal 2026, or approximately 20.5% of company revenue for that period, including $152 million of Entrust revenue.

  • Segment

    Defense

    Description

    Provides defense platforms, systems engineering, research and development, space and missile-related capabilities, naval and aerospace support, and other defense products and services.

    Fiscal 2025 Revenue

    $2.030 billion under the prior reporting structure, equal to approximately 12.2% of company revenue.

    Current 2026 Indicator

    Revenue was $1.838 billion in the first six months of fiscal 2026, or approximately 20.5% of company revenue for that period.

Revenue Split

Fiscal 2025 Total Revenue

$16.662 billion for the fiscal year ended January 2, 2026.

Fiscal 2025 Segment Split

  • National Security & Digital: $7.365 billion, approximately 44.2%.
  • Health & Civil: $5.015 billion, approximately 30.1%.
  • Commercial & International: $2.252 billion, approximately 13.5%.
  • Defense Systems: $2.030 billion, approximately 12.2%.

Fiscal 2025 Geography

  • United States: $15.703 billion, approximately 91.8% of revenue.
  • International: $1.404 billion, approximately 8.2% of revenue.

Government Exposure

  • Approximately 87% of fiscal 2025 revenue came from contracts with the U.S. government, either directly or through subcontracting arrangements.
  • Contracts involving the Department of War and the U.S. Intelligence Community represented approximately 49% of fiscal 2025 revenue.
  • In the first six months of fiscal 2026, approximately 85% of revenue came from U.S. government contracts and approximately 8% came from international customers.

Main Customers

  • Major customers include the U.S. Department of War, U.S. Intelligence Community, Department of Homeland Security, Federal Aviation Administration, Department of Veterans Affairs, Defense Health Agency, Transportation Security Administration, Customs and Border Protection, military services, civilian agencies, state and local governments, foreign governments, NATO, and commercial customers.
  • International customers specifically identified by Leidos include the United Kingdom Ministry of Defence, Australian Department of Defence, and NATO.

Revenue Character

  • Revenue is contract-based and relatively visible because of funded backlog, multiyear contracts, and task orders, but it is not predominantly subscription revenue.
  • The business is best described as recurring and programmatic rather than contractual annuity-like. Customers frequently renew, recompete, or expand programs, but individual contracts can end, be delayed, lose recompetes, or experience funding changes.
  • Leidos has a mixture of cost-reimbursement, fixed-price-incentive, firm-fixed-price, time-and-materials, and fixed-price-level-of-effort contracts. Firm-fixed-price work can offer attractive margins but creates greater execution risk if costs exceed estimates.
  • The business is less economically cyclical than commercial technology or industrial businesses because national-security and public-sector demand is supported by government budgets, but it remains sensitive to appropriations, continuing resolutions, shutdowns, changing priorities, inflation, contract protests, and competitive rebids.

Backlog

  • As of July 3, 2026, total estimated backlog was $48.711 billion, including $10.223 billion of funded backlog and $38.488 billion of unfunded backlog.
  • Backlog includes negotiated contracts and certain sole-source IDIQ task orders considered probable, but it excludes potential task orders under multiple-award IDIQ contracts. Therefore, backlog is an indicator of revenue visibility rather than guaranteed future revenue.

History

Origin

  • The company traces its origins to 1969, when physicist J. Robert Beyster founded Science Applications International Corporation.
  • The modern Leidos entity was created through the 2013 separation of the original SAIC. On September 27, 2013, the technical-services and enterprise-information-technology business became the separately traded company named Science Applications International Corporation, while the remaining business was renamed Leidos Holdings.

Key Milestones

  • Date

    September 27, 2013

    Event

    SAIC separation and rebranding created Leidos as an independent public company focused on defense, intelligence, health, engineering, and related technology markets.

  • Date

    August 16, 2016

    Event

    Leidos completed its combination with Lockheed Martin's Information Systems & Global Solutions business through a Reverse Morris Trust transaction. The transaction substantially increased Leidos's scale in federal information technology, systems integration, and mission support.

  • Date

    August 15, 2019

    Event

    Leidos acquired IMX Medical Management Services, expanding its independent medical evaluation capabilities.

  • Date

    January 31, 2020

    Event

    Leidos acquired Dynetics for approximately $1.6 billion, adding applied research, advanced defense, space, hypersonics, and national-security capabilities.

  • Date

    May 4, 2020

    Event

    Leidos acquired the Security Detection & Automation businesses of L3Harris for approximately $1.0 billion, expanding aviation, transportation-security, screening, and automation capabilities.

  • Date

    2021

    Event

    Leidos acquired Gibbs & Cox, adding naval architecture, marine engineering, and ship-design capabilities.

  • Date

    May 3, 2023

    Event

    Thomas A. Bell became chief executive officer, succeeding Roger Krone. Robert Shapard became independent board chair.

  • Date

    May 23, 2025

    Event

    Leidos acquired Savanna Industries, known as Kudu Dynamics, to strengthen cyber and specialized digital capabilities.

  • Date

    March 27, 2026

    Event

    Leidos completed its acquisition of Entrust Solutions Group for approximately $2.4 billion, adding utility engineering, power, and infrastructure-design capabilities.

Leadership

  • Roger Krone served as chairman and chief executive officer from 2014 until 2023 and led the company through the Lockheed Martin IS&GS combination and the Dynetics and L3Harris acquisitions.
  • Thomas A. Bell has served as chief executive officer since May 3, 2023. His background includes senior leadership at Rolls-Royce and Boeing.
  • Bell's current strategic framework, NorthStar 2030, emphasizes defense technology, managed health, digital infrastructure and cyber, energy resilience, and mission software.

Interpretation

  • Leidos's history is defined less by a single proprietary product than by assembling a broad portfolio of mission-critical capabilities through corporate separation, major combinations, and targeted acquisitions.
  • The Lockheed Martin transaction was the pivotal scale event; Dynetics broadened advanced-defense capabilities; Kudu strengthened cyber; and Entrust materially increased exposure to energy infrastructure and commercial-adjacent engineering.
  • The acquisition-led history creates both an advantage and a risk: scale and cross-selling improve positioning, but integration, leverage, goodwill, and margin dilution can reduce shareholder returns if acquired businesses underperform.

Strengths and Moat

Strengths

  • Factor

    Mission-critical customer relationships

    Fact

    Leidos supports sensitive national-security, defense, health, transportation, and homeland-security missions for numerous government agencies.

    Interpretation

    Strong execution history, institutional knowledge, security clearances, and customer familiarity can make Leidos a credible incumbent and reduce the risk of displacement on complex programs.

  • Factor

    Scale and contract access

    Fact

    The company has approximately 50,000 employees, multibillion-dollar annual revenue, broad contract-vehicle access, and a large backlog.

    Interpretation

    Scale helps Leidos absorb compliance costs, maintain cleared technical talent, bid on large programs, and combine hardware, software, engineering, and managed services in a single proposal.

  • Factor

    Breadth of capabilities

    Fact

    The portfolio spans intelligence, cyber, defense, health, aviation security, border systems, engineering, energy infrastructure, and digital modernization.

    Interpretation

    Breadth can support cross-selling and make Leidos more relevant to large, multidomain government programs. It also reduces dependence on any one mission area, although the portfolio remains heavily dependent on U.S. government spending overall.

  • Factor

    Backlog and funding visibility

    Fact

    Leidos reported $48.711 billion of estimated backlog as of July 3, 2026, including $10.223 billion funded.

    Interpretation

    Backlog supports medium-term revenue visibility, but the large unfunded component is not equivalent to contracted cash flow and remains subject to appropriations, task-order awards, modifications, and execution.

  • Factor

    Security and regulatory barriers

    Fact

    Many programs require security clearances, specialized facilities, compliance systems, past performance, and technical qualifications.

    Interpretation

    These requirements create meaningful barriers to entry for smaller or newer competitors, particularly in classified and mission-critical work.

Competitors

  • Leidos identifies Accenture Federal Services, Amentum, BAE Systems, Booz Allen Hamilton, CACI International, Deloitte, General Dynamics, GovCIO, IBM, KBR, L3Harris Technologies, Lockheed Martin, ManTech, Northrop Grumman, Optum, Parsons, Peraton, RTX, and SAIC among its principal competitors.
  • Competition varies by program: Leidos faces large defense primes in systems and platforms, professional-services firms in consulting and digital work, specialized government contractors in intelligence and cyber, and commercial or industrial engineering firms in energy and infrastructure.

Where It Wins

  • Large, complex programs that require a combination of cleared personnel, systems integration, engineering, digital capabilities, operational support, and past performance.
  • Programs where incumbent knowledge, customer trust, security infrastructure, and the ability to manage distributed delivery are more important than a single low-cost product.
  • Cross-domain opportunities that connect defense, intelligence, health, homeland security, cyber, and infrastructure capabilities.

Where It Loses

  • Highly competitive procurements where price is the main differentiator and services are difficult to distinguish.
  • Programs requiring leading-edge commercial software platforms or consumer-scale product economics, where Leidos may compete against more focused technology companies.
  • Contracts exposed to fixed-price execution risk, labor shortages, supply-chain problems, schedule delays, or unfavorable changes in program scope.
  • Situations where a customer consolidates work with a larger incumbent, changes procurement vehicles, or shifts budget priorities.

Moat Assessment

Rating

Moderate and durable in selected niches, but not a wide corporate moat.

Durability

  • The strongest elements are accumulated past performance, security clearances, contract vehicles, technical workforce, classified infrastructure, compliance capabilities, and embedded customer knowledge.
  • These advantages are durable because they take time and money to build, but they do not eliminate competition. Government customers intentionally encourage competition, recompetes, multiple-award contracting, and price pressure.
  • Leidos's moat is therefore relationship- and execution-based rather than protected by patents, network effects, consumer switching costs, or a dominant proprietary software ecosystem.
  • The moat should be most durable in classified, technically complex, mission-critical, and operationally embedded programs. It is weaker in commoditized IT services, labor-based staffing, and open competitive bids where customers can compare providers largely on price and proposal quality.

Key Threats

  • Federal budget reductions or shifts away from the company's priority markets.
  • Losses on major recompetes or failure to win follow-on work.
  • Margin pressure from fixed-price contracts, wage inflation, subcontractor costs, and aggressive bidding.
  • Integration risk and leverage following acquisitions, especially Entrust.
  • Customer insourcing, commercial technology substitution, or procurement reform that lowers barriers to switching providers.

Bottom line

Leidos is a diversified government technology and mission-services contractor that earns most of its revenue from U.S. government programs across defense, intelligence, health, homeland security, cyber, and infrastructure. Its differentiation comes from scale, cleared talent, contract access, past performance, and the ability to integrate complex mission capabilities, but its moat is narrower than that of a proprietary software or platform company. The most important long-term variables are federal spending and priorities, recompete performance, fixed-price contract execution, the profitability of newer growth areas, and whether acquisitions such as Entrust create durable organic growth without excessive leverage or integration costs.

Advertisement

Part 2

Updated 2026-11-18

Current Situation & Why the Stock Is in a Rut

Leidos is operationally healthier than its share price suggests, but the November 3, 2026 earnings reaction exposed why the stock remains stuck: revenue missed expectations, full-year revenue guidance was reduced, Health remained weak, and investors received limited visibility into fiscal 2027 growth despite stronger EPS and cash flow.

Recent Performance

Stock Context

  • LDOS was approximately $130.02 on November 17, 2026, versus a reported 52-week high of approximately $205.00, leaving the shares roughly 37% below that high.
  • The scanner snapshot reports a trailing P/E of approximately 11.7x, price-to-book of approximately 3.1x, and free cash flow of approximately $1.63 billion. The scanner's dividend data should be treated cautiously because its $1.72 annual dividend figure differs from Leidos's more recently declared $0.45 quarterly dividend.

Last Three Reports

  • Date

    February 17, 2026

    Period

    Q4 fiscal 2025

    Facts

    • Revenue was $4.207 billion, down 4% year over year.
    • GAAP diluted EPS was $2.53 and non-GAAP diluted EPS was $2.76.
    • Adjusted EBITDA was $556 million, with a 13.2% margin versus 11.6% in the prior-year quarter.
    • Management attributed part of the revenue decline to a six-week government shutdown and an extra work week in the prior-year comparison.
    • Initial fiscal 2026 guidance called for revenue of $17.5 billion to $17.9 billion, non-GAAP EPS of $12.05 to $12.45, a mid-13% adjusted EBITDA margin, and approximately $1.75 billion of operating cash flow.
    • Leidos also announced the approximately $2.4 billion Entrust Solutions acquisition, creating immediate concerns about leverage and integration.

    Expectations And Stock Pressure

    • Revenue missed the Wall Street expectation cited in contemporaneous reporting.
    • The midpoint of initial fiscal 2026 EPS guidance was below the cited analyst expectation.
    • The combination of a revenue miss, government-shutdown disruption, conservative guidance, and the Entrust acquisition weakened the stock's prior earnings and margin-recovery narrative.
  • Date

    May 5, 2026

    Period

    Q1 fiscal 2026

    Facts

    • Revenue was $4.400 billion, up 4% year over year and above the cited consensus estimate of $4.283 billion.
    • GAAP diluted EPS was $2.56 versus $2.77 in the prior-year quarter; non-GAAP diluted EPS was $3.13 versus $2.90 expected in the cited estimate.
    • Adjusted EBITDA was $614 million, with a 14.0% margin versus 14.2% a year earlier.
    • Quarterly bookings were approximately $3.3 billion, producing a book-to-bill ratio of 0.8. Trailing-twelve-month book-to-bill was 1.1 and total backlog increased 4% year over year.
    • Management raised fiscal 2026 revenue guidance to $18.0 billion to $18.4 billion, non-GAAP EPS guidance to $12.10 to $12.50, and operating-cash-flow guidance to approximately $1.80 billion.
    • Debt was approximately $6.3 billion at April 3, 2026, following the Entrust transaction.

    Expectations And Stock Pressure

    • The quarter beat the cited revenue and adjusted-EPS expectations, but GAAP EPS declined, margin was slightly lower year over year, quarterly book-to-bill was below 1.0, and leverage increased materially.
    • Those factors limited the market's willingness to treat the quarter as evidence of a durable reacceleration.
  • Date

    August 4, 2026

    Period

    Q2 fiscal 2026

    Facts

    • Revenue was $4.558 billion, up 7% year over year and approximately 4% organically.
    • GAAP diluted EPS was $2.81 versus $3.01 in the prior-year quarter; non-GAAP diluted EPS was $3.26 versus $3.21.
    • Adjusted EBITDA was $631 million versus $647 million, and adjusted EBITDA margin declined to 13.8% from 15.2%.
    • Operating cash flow was $793 million and non-GAAP free cash flow was $761 million.
    • Net bookings were approximately $5 billion, and management raised fiscal 2026 revenue guidance to $18.2 billion to $18.4 billion, non-GAAP EPS guidance to $12.20 to $12.50, and operating-cash-flow guidance to approximately $1.85 billion.

    Expectations And Stock Pressure

    • The quarter was strong on revenue, adjusted EPS, bookings, cash flow, and guidance, but the 140-basis-point adjusted-EBITDA-margin decline reinforced concerns about earnings quality and margin durability.
    • The improvement in non-GAAP EPS was only 2% despite 7% reported revenue growth, which reduced the impact of the headline beat.
  • Date

    November 3, 2026

    Period

    Q3 fiscal 2026

    Facts

    • Revenue was $4.630 billion, up 4% year over year, but below the cited analyst estimate of approximately $4.71 billion.
    • GAAP diluted EPS was $3.28 versus $2.82 in the prior-year quarter; non-GAAP diluted EPS was $3.62 versus $3.05 and above the cited consensus estimate of approximately $3.04 to $3.05.
    • Adjusted EBITDA was $644 million, up 5%, and adjusted EBITDA margin was 13.9% versus 13.8% a year earlier.
    • Operating cash flow was $523 million and non-GAAP free cash flow was $476 million.
    • Net bookings were $5.5 billion, book-to-bill was 1.2, total backlog was $49.6 billion, and funded backlog was $11.1 billion.
    • Health revenue declined 12% to $1.07 billion and Health operating margin fell to 22.5% from 26.8%. Homeland revenue rose 32%, partly because of $142 million of Entrust revenue.
    • Leidos lowered fiscal 2026 revenue guidance to $18.0 billion to $18.2 billion from $18.2 billion to $18.4 billion, while raising non-GAAP EPS guidance to $12.50 to $12.70 and operating-cash-flow guidance to approximately $1.90 billion.
    • The revenue-guidance reduction reflected the October 5, 2026 closing and reset of the SES joint venture structure, but the lower sales outlook still signaled weaker top-line visibility.

    Stock Pressure

    • Shares fell sharply after the report in contemporaneous market coverage, despite the adjusted-EPS beat.
    • The negative reaction was driven by the revenue miss, lower full-year revenue outlook, persistent Health weakness, and concern that strong EPS was being supported more by cost control, tax effects, mix, and share repurchases than by broad-based organic growth.
    • Management's fiscal 2027 outlook was reportedly cautious, but the precise fiscal 2027 figures were not verified from a primary company filing and are therefore treated as unverified.

Overall Read

  • The earnings record is mixed for shareholders but not indicative of an operational collapse: revenue increased in each of the first three fiscal 2026 quarters, bookings improved in Q3, backlog grew, cash flow remained strong, and EPS guidance was raised three times.
  • The main weakness is growth quality. Organic growth has been modest, Health is contracting, and the latest revenue guidance was reduced even as adjusted EPS guidance increased.
  • The stock is being valued on confidence in normalized future earnings rather than on isolated adjusted-EPS beats.

The Bear Case

Company Specific Problems

  • Health deterioration is the clearest current issue. Q3 Health revenue fell 12% year over year and operating margin declined 430 basis points to 22.5%; nine-month Health revenue and operating income were also below the prior-year period.
  • Leidos has a low-growth profile relative to premium defense-technology companies. Q3 reported revenue growth was 4%, while the company reduced full-year revenue guidance to $18.0 billion to $18.2 billion.
  • Entrust added revenue and backlog but also increased execution complexity and leverage. Debt was $6.0 billion at October 2, 2026, versus $4.6 billion at January 2, 2026, and quarterly interest expense rose to $67 million from $51 million.
  • The Q3 revenue increase included $142 million of Entrust revenue, making reported growth less representative of underlying organic growth.
  • Backlog quality is not equivalent to near-term revenue. Of $49.6 billion of total backlog at October 2, 2026, $11.1 billion was funded; the remainder depends on future appropriations, task-order timing, options, and contract execution.
  • Nine-month operating income declined to $1.575 billion from $1.636 billion, while nine-month net income attributable to Leidos common shareholders declined to $1.092 billion from $1.121 billion.
  • Leidos remains exposed to contract protests, fixed-price execution risk, labor and clearance constraints, cybersecurity incidents, procurement delays, and the risk that acquisition or restructuring charges remain elevated.

Macro And Sector Headwinds

  • Approximately 83% of Q3 revenue came from contracts with the U.S. government, leaving Leidos sensitive to appropriations, continuing resolutions, shutdowns, changes in agency priorities, and procurement delays.
  • Federal civilian and healthcare spending may be more exposed to budget controls than certain defense-modernization programs.
  • Higher interest rates and higher government bond yields reduce the valuation investors may assign to a mature, leveraged government-services contractor.
  • The defense and government-services sector has been less favored than higher-growth technology and AI-linked equities during portions of 2026, creating sector-level multiple pressure.
  • A continuing resolution through fiscal 2026 was included in management's guidance assumptions, so a materially different budget environment could pressure delivery against the outlook.

Valuation

  • At approximately $130.02 and a scanner-reported trailing P/E of approximately 11.7x, LDOS is inexpensive relative to the broad market but not obviously distressed on an absolute earnings basis.
  • Using the midpoint of current non-GAAP EPS guidance of $12.60, the shares trade at approximately 10.3x forward non-GAAP EPS. This is attractive if guidance is achieved but excludes amortization and other items that reduce GAAP earnings.
  • Third-party historical ratio data show forward P/E levels of approximately 15.6x for fiscal 2025, 14.4x for fiscal 2024, 14.6x for fiscal 2023, 15.4x for fiscal 2022, and 12.9x for fiscal 2021. On that basis, the current approximately 11.4x to 11.7x forward or trailing valuation is below several recent historical levels.
  • A consistent, same-date peer valuation set for CACI, SAIC, and Booz Allen was not verified from primary sources in this review. The directional conclusion is that LDOS trades at a discount to faster-growing or more technology-oriented contractors, but the discount is partly justified by slower organic growth, Health weakness, leverage, and lower confidence in fiscal 2027.
  • The valuation discount is not automatically a mispricing: a low-teens or high-single-digit multiple may be appropriate if Leidos remains a mature, low-growth systems integrator with limited margin expansion.

Analyst Positioning

  • JPMorgan downgraded Leidos from Overweight to Neutral on October 8, 2026 and cut its price target from $160 to $142, citing margin concerns and weakness in the Health division.
  • The broader analyst stance remains mixed rather than uniformly bearish. Third-party consensus data report a Buy or Moderate Buy consensus with many Hold ratings and no broad sell-side capitulation.
  • Recent target changes after the Q3 report included both positive and negative revisions in third-party data, suggesting disagreement over whether the lower revenue outlook is temporary or marks a lower growth trajectory.

Short Interest

  • Reported short interest was approximately 3.91 million shares as of October 30, 2026, equal to approximately 3.23% of public float.
  • That level is meaningful but not extreme. It can amplify a rebound if estimates improve, but it does not indicate a heavily crowded short thesis.

Turnaround or Value Trap?

Bull Case

  • Leidos has substantial government revenue visibility, $49.6 billion of backlog, $11.1 billion of funded backlog, and a Q3 book-to-bill ratio of 1.2.
  • Management has raised full-year EPS and cash-flow guidance three times during fiscal 2026, which is stronger evidence than a single quarterly beat.
  • Q3 bookings included sizeable awards in intelligence, air traffic management, cyber, missile defense, transportation security, and military health, supporting demand in several strategic areas.
  • Q3 adjusted EBITDA margin stabilized at 13.9% and exceeded the prior-year margin, while Q3 free cash flow was $476 million.
  • At approximately 10.3x midpoint forward non-GAAP EPS, even modest earnings growth, debt reduction, or a return toward the company's recent valuation range could support a re-rating.
  • Leidos repurchased approximately $504 million of stock in Q3 and raised its quarterly dividend to $0.45 per share, indicating strong capital-generation capacity if leverage remains manageable.

Bear Case

  • The Q3 revenue miss and lower revenue guidance suggest that EPS growth may be outpacing the underlying sales trajectory.
  • Health is a significant earnings risk because both revenue and margins declined materially, and the segment had been one of the company's higher-margin businesses.
  • Entrust may add revenue without generating sufficient return on invested capital if integration costs, amortization, interest expense, or contract execution issues remain elevated.
  • The Q3 EPS beat benefited partly from a lower effective tax rate and other adjustments, so GAAP earnings and cash conversion remain important checks on earnings quality.
  • If fiscal 2027 begins with flat or declining EPS, the current low multiple may represent a fair risk-adjusted valuation rather than a temporary anomaly.
  • Federal budget delays or a new shutdown could defer backlog conversion and make current guidance difficult to achieve.

What Must Happen For Recovery

  • Health revenue should stabilize, with segment margins returning toward the low-to-mid-20% range without relying on one-time benefits.
  • Organic revenue growth should sustain at approximately 4% to 6% or better, with reported growth increasingly coming from internal expansion rather than Entrust contribution.
  • Adjusted EBITDA margin should remain around or above the mid-13% guidance range and show credible expansion in fiscal 2027.
  • Quarterly book-to-bill should remain at or above 1.0, while funded backlog growth converts into revenue rather than remaining primarily unfunded.
  • Debt should decline from the approximately $6.0 billion level, and interest expense should stop rising faster than operating income.
  • Entrust integration should produce measurable synergies, stable margins, and declining acquisition-related charges.
  • Management should provide a credible fiscal 2027 outlook showing at least stable EPS and improving organic growth.

Key Catalysts And Dates

  • The next confirmed company earnings date was not identified in the reviewed primary sources. A future Q4 fiscal 2026 report is expected, but the exact date is unverified.
  • The December 31, 2026 dividend payment, based on the October 30 declaration, is a shareholder-return event but is unlikely to be a major valuation catalyst.
  • The most important near-term catalyst is evidence that Q3's improved book-to-bill and backlog growth convert into fourth-quarter and fiscal 2027 revenue.
  • Potential positive catalysts include large defense, intelligence, cyber, air-traffic-management, or infrastructure awards, lower debt, successful Entrust integration, and Health-margin stabilization.

Metrics To Watch

  • Organic revenue growth by segment, especially Health, Intelligence & Digital, Defense, and Homeland.
  • Health revenue, operating margin, and program-volume trends.
  • Adjusted EBITDA margin and GAAP operating margin.
  • Quarterly and trailing-twelve-month book-to-bill.
  • Funded backlog growth and conversion into reported revenue.
  • Operating cash flow, free-cash-flow conversion, debt repayment, and interest expense.
  • Entrust revenue contribution, integration costs, amortization, and realized synergies.
  • Fiscal 2027 EPS and revenue guidance when management first provides it.

Assessment

The bull case is credible because bookings, backlog, cash flow, and EPS guidance have improved. The value-trap risk is also real because Q3 revenue missed expectations, full-year revenue guidance was reduced, Health weakened sharply, and leverage remains elevated. Recovery requires confirmation that the business can produce organic growth and Health stabilization rather than merely repeated adjusted-EPS beats.

Evidence Assessment

Conclusion

Evidence is more consistent with temporary-to-cyclical pressure layered on top of moderate structural valuation constraints than with a severe structural business breakdown, but the evidence is not strong enough to rule out a value trap.

Why

  • Evidence supporting temporary pressure includes strong Q3 bookings, a 1.2 book-to-bill ratio, rising funded backlog, improved adjusted EBITDA margin, repeated EPS-guidance increases, and strong cash generation.
  • Evidence supporting structural concerns includes Health revenue and margin deterioration, modest organic growth, lower full-year revenue guidance, increased leverage, higher interest expense, and limited visibility into fiscal 2027.
  • The stock's failure to respond positively to multiple earnings and guidance beats suggests that investors are discounting the durability and quality of earnings rather than simply reacting to quarterly EPS.
  • The most balanced interpretation is that Leidos is not currently showing a broad operational failure, but the market is demanding proof of sustainable organic growth, Health stabilization, deleveraging, and fiscal 2027 earnings visibility before assigning a higher multiple.

Bottom line

Leidos is a diversified government technology, defense, intelligence, healthcare, infrastructure, cyber, and mission-services contractor with substantial backlog and strong cash generation. The stock is stuck because investors are balancing improved EPS, bookings, and cash flow against a Q3 revenue miss, reduced full-year revenue guidance, Health deterioration, higher leverage, and uncertainty about fiscal 2027 growth. The next decisive signals are Health stabilization, organic revenue growth, book-to-bill above 1.0, debt reduction, Entrust execution, and the company's first credible fiscal 2027 outlook.

Advertisement
Advertisement

Research history

The current situation refreshes after a gap or at the 30-day consecutive Top-10 refresh point. Previous analyses are retained.